Singapore markets close in 1 hour 19 minutes

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.02-0.14 (-1.72%)
At close: 04:00PM EDT
8.02 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.16
Open8.26
Bid7.94 x 100
Ask8.19 x 100
Day's range8.02 - 8.69
52-week range3.21 - 9.96
Volume52,106
Avg. volume78,626
Market cap244.216M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date15 Jul 2021
1y target estN/A
All
News
  • GlobeNewswire

    XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

    XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility XBiotech Architectural Rendition of XBiotech’s Planned R&D Facility AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new fou

  • GlobeNewswire

    Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

    (Phase II Multicenter Study is Proceeding Well with High Anticipation)AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for rheumatological diseases. The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Con